INTEGRA Biosciences and Viaflo Corporation Join Forces
News Aug 18, 2009
The combining of the two companies provides for strong mutual benefits. INTEGRA Biosciences will be receiving direct access to the important US Market through the Viaflo sales network. INTEGRA Biosciences also receives access to a complete line of new and innovative handheld pipetting systems and associated plastic disposables. Viaflo will receive strong representation and access to European and global markets through INTEGRA Biosciences and their large network of specialist distributors. In the USA - Viaflo will also benefit from selling the complimentary, well recognised, and established INTEGRA Biosciences product portfolio. The INTEGRA Biosciences and Viaflo products complement each other perfectly.
The new group, in the last 2 years has translated customer needs into the introduction of many new innovative and reliable products. With specialists in sales, marketing, research, development and manufacturing it maintains close relations and collaborations with customers worldwide for the purpose of providing cutting edge technologies to the health care industry.
As a result of constant growth achieved over recent years, INTEGRA Biosciences has announced that it will also move from its current location into a larger new modern industrial building in Zizers, Switzerland.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.